ArticleVirology journal2025
Isolation and characterization of a novel bacteriophage PUTH1 active against Pseudomonas aeruginosa.
Article in Virology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Characterization and comparative genomic analysis of a novel bacteriophage against an extremely drug-resistantMicrobiology spectrum · 2026Article
- A comprehensive analysis of the kinetics of infection of lytic bacteriophages specific to the ESKAPE and critical pathogens.World journal of microbiology & biotechnology · 2026Review
- A theoretical exploration of protocols for treating prosthetic joint infections with combinations of antibiotics and bacteriophage.NPJ biofilms and microbiomes · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundPseudomonas aeruginosa (P. aeruginosa) is a leading cause of healthcare-associated infection and is prone to antibiotic resistance. Treating infections caused by antibiotic-resistant P. aeruginosa remains clinically challenging. The increasing prevalence of multidrug-resistant (MDR) bacteria has prompted the development of alternatives to antibiotics. Bacteriophage (phage) therapy has been regarded as a promising antibacterial alternative in many cases of MDR bacterial infections. This study aimed to isolate and characterize phages with therapeutic potential against MDR P. aeruginosa.
methodsPhage PUTH1 was isolated from filtered sewage water collected at Peking University Third Hospital using the double-layer agar spot method. The phage morphology was characterized using transmission electron microscopy (TEM). Subsequently, key biological properties were evaluated, including temperature and pH stability, one-step growth curve, adsorption rate, and optimal multiplicity of infection (MOI). Additionally, the anti-biofilm activity was assessed using crystal violet staining assays. Finally, whole genome sequencing was conducted, followed by comprehensive bioinformatics analysis.
resultsMorphological and genomic characterization confirmed that the phage PUTH1 belongs to the Podoviridae family. The phage exhibits remarkable thermal stability (active up to 60 °C) and across a broad pH range (pH 4.0–9.0). Furthermore, the phage is characterized by a short latent period (approximately 30 min), a large burst size (54.5 PFU/cell), and rapid adsorption efficiency, achieving approximately 80% adsorption after 6 min. PUTH1 exhibits significant anti-biofilm activity. The genome of phage was 45,483 bp with 52.25% GC content and contained 70 putative genes; functions were predicted for 32 of them. Phylogenetic analysis revealed that PUTH1 is distinct from currently known phages and belongs to a novel species. The genome sequencing analysis suggested that it does not exist any known virulence and antibiotic resistant genes.
conclusionTherefore, our findings demonstrate that this novel phage represents a promising therapeutic candidate for treating MDR P. aeruginosa infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.